Journal article

Adequate SIRT activity dose is as important as adequate chemotherapy dose Reply

Ricky A Sharma, Peter Gibbs, Navesh K Sharma, Jens Ricke, Julien Taieb, Joanna Moschandreas, Pradeep S Virdee, Peter Dutton, Guy van Hazel, Harpreet S Wasan

The Lancet Oncology | ELSEVIER SCIENCE INC | Published : 2017

Grants

Funding Acknowledgements

HSW reports grants, personal fees, non-financial support, and other uncompensated work from Sirtex Medical; grants, personal fees, non-financial support, and other support from Merck Serono and Celgene; grants and other support from Pfizer; and personal fees and non-financial support from Roche and Lily outside the submitted work. PG reports personal fees from SIRTEX and grants and personal fees from Roche, Amgen, Pfizer, Merck, Bayer, and Servier, during the study. NKS reports other support from Sirtex Medical outside the submitted work. JR reports personal fees from Sirtex during the study and grants from Sirtex outside the submitted work. JM, and PD report grants from Cancer Research UK and grants from Sirtex Medical during the study and non-financial support from Sirtex Medical outside the submitted work. PSV reports grants from Sirtex Medical and grants from Cancer Research UK during the conduct of the study. GvH reports personal fees and non-financial support from Sirtex, during the study and personal fees and non-financial support from SiRTEX, outside the submitted work. RAS reports grants, personal fees, and other support from Sirtex and BTG, during the study, and personal fees from Affidea, AstraZeneca, Boston Scientific, Cancer Research Technology, Eisai, Terumo, and Varian, outside the submitted work. JT declares no competing interests. RAS, HSW, PG, and GvH contributed equally to the writing of this Correspondence.